Prevention of in vivo lung tumor growth by prolonged local delivery of hydroxycamptothecin using poly(ester-carbonate)-collagen composites

Journal of Controlled Release

Volumn 144, Issue 3, 2010, Pages 280-287

  Wolinsky, Jesse B ^a,b   Liu, Rong ^c   Walpole, Joe ^c   Chirieac, Lucian R ^c   Colson, Yolonda L ^c   Grinstaff Mark W , M W ^a,b  

^a Boston University   (United States)

^b USA   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Films; Local delivery; Lung tumors; Prevention; Recurrence

Indexed keywords

ANTI-CANCER AGENTS; CAPROLACTONE; COLLAGEN COMPOSITES; COLLAGEN-BASED SCAFFOLDS; DRUG-LOADED FILMS; FLEXIBLE COMPOSITES; GLYCEROL MONOSTEARATE; HYDROXYCAMPTOTHECIN; IN-VIVO; LEWIS LUNG CARCINOMATA; LOCAL DELIVERY; LOCAL RECURRENCE; LOW DOSE; LUNG CANCER; LUNG TISSUE; LUNG TUMOR; LUNG TUMORS; MATRIX; SURGICAL RESECTION; SURGICAL TREATMENT; SYSTEMIC THERAPY; TUMOR GROWTH;

ANIMALS; BIOLOGICAL ORGANS; COLLAGEN; COMPOSITE FILMS; DISEASE CONTROL; DISEASES; ESTERS; GLYCEROL;

TUMORS;

10 HYDROXYCAMPTOTHECIN; COLLAGEN; COPOLYMER; POLY(ESTER) CARBONATE; POLY(GLYCEROL CO EPSILON CAPROLACTONE); POLY(GLYCEROL MONOSTEARATE CO EPSILON CAPROLACTONE); UNCLASSIFIED DRUG; 10-HYDROXYCAMPTOTHECIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DELAYED RELEASE FORMULATION; DRUG CARRIER; POLY(GLYCEROL MONOSTERATE-CO-EPSILON-CAPROLACTONE); POLYESTER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG RELEASE; FEMALE; IN VIVO STUDY; LEWIS CARCINOMA; LUNG PARENCHYMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; ANALOGS AND DERIVATIVES; ANIMAL; CARCINOMA, LEWIS LUNG; CELL PROLIFERATION; CELL SURVIVAL; CHEMISTRY; DELAYED RELEASE FORMULATION; DRUG EFFECTS; DRUG FORMULATION; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; SCANNING ELECTRON MICROSCOPY; SURFACE PROPERTY; TISSUE SCAFFOLD; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CARCINOMA, LEWIS LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; COLLAGEN; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; DRUG COMPOUNDING; MICE; MICROSCOPY, ELECTRON, SCANNING; NEOPLASM RECURRENCE, LOCAL; POLYESTERS; SURFACE PROPERTIES; TISSUE SCAFFOLDS;

EID: 77953287618     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2010.02.022     Document Type: Article

References (38)

1. Saltzman W.M., Fung L.K. Polymeric implants for cancer chemotherapy. Adv. Drug Deliv. Rev. 1997, 26:209-230.
2. Allen T.M., Cullis P.R. Drug delivery systems: entering the mainstream. Science 2004, 303:1818-1822.
3. Moses M.A., Brem H., Langer R. Advancing the field of drug delivery: taking aim at cancer. Cancer Cell 2003, 4:337-341.
4. Wong S.J., Machtay M., Li Y. Locally recurrent, previously irradiated head and neck cancer: concurrent re-irradiation and chemotherapy, or chemotherapy alone?. J. Clin. Oncol. 2006, 24:2653-2658.
5. Clemons M., Danson S., Hamilton T., Goss P. Locoregionally recurrent breast cancer: incidence, risk factors and survival. Cancer. Treat. Rev. 2001, 27:67-82.
6. El-Sherif A., Fernando H.C., Santos R., Pettiford B., Luketich J.D., Close J.M., Landreneau R.J. Margin and local recurrence after sublobar resection of non-small cell lung cancer. Ann. Surg. Oncol. 2007, 14:2400-2405.
7. Read T.E., Mutch M.G., Chang B.W., McNevin M.S., Fleshman J.W., Birnbaum E.H., Fry R.D., Caushaj P.F., Kodner I.J. Locoregional recurrence and survival after curative resection of adenocarcinoma of the colon. J. Am. Coll. Surg. 2002, 195:33-40.
8. Moriya Y. Treatment strategy for locally recurrent rectal cancer. Jpn. J. Clin. Oncol. 2006, 36:127-131.
9. Newman E.A., Simeone D.M., Mulholland M.W. Adjuvant treatment strategies for pancreatic cancer. J. Gastrointest. Surg. 2006, 10:916-926.
10. Oshita F., Saito H., Yamada K., Noda K. Phase II study of paclitaxel and irinotecan chemotherapy in patients with advanced nonsmall cell lung cancer. Am. J. Clin. Oncol. 2007, 30:358-360.
11. Kawahara M. Irinotecan in the treatment of small cell lung cancer: a review of patient safety considerations. Expert Opin. Drug Safety 2006, 5:303-312.
12. Wolinsky J.B., Ray W.C., Colson Y.L., Grinstaff M.W. Poly(carbonate-ester)s based on units of 6-hydroxyhexanoic acid and glycerol. Macromolecules 2007, 40:7065-7068.
13. Chollet D.F., Goumaz L., Renard A., Montay G., Vernillet L., Arnera V., Mazzo D.J. Simultaneous determination of the lactone and carboxylate forms of the camptothecin derivative CPT-11 and its metabolite SN-38 in plasma by high-performance liquid chromatography. J. Chromatogr., B, Biomed. Sci. Appl. 1998, 718:163-175.
14. Ertl B., Platzer P., Wirth M., Gabor F. Poly(d, l-lactic-co-glycolic acid) microspheres for sustained delivery and stabilization of camptothecin. J. Control. Release 1999, 61:305-317.
15. Burke T.G., Mi Z. Ethyl substitution at the 7 position extends the half-life of 10-hydroxycamptothecin in the presence of human serum albumin. J. Med. Chem. 1993, 36:2580-2582.
16. Pitt C.G., Gratzl M.M., Jeffcoat A.R., Zweidinger R., Schindler A. Sustained drug delivery systems II: factors affecting release rates from poly(epsilon-caprolactone) and related biodegradable polyesters. J. Pharm. Sci. 1979, 68:1534-1538.
17. Ping Y.H., Lee H.C., Lee J.Y., Wu P.H., Ho L.K., Chi C.W., Lu M.F., Wang J.J. Anticancer effects of low-dose 10-hydroxycamptothecin in human colon cancer. Oncol. Rep. 2006, 15:1273-1279.
18. Shenderova A., Burke T.G., Schwendeman S.P. Stabilization of 10-hydroxycamptothecin in poly(lactide-co-glycolide) microsphere delivery vehicles. Pharm. Res. 1997, 14:1406-1414.
19. Hatefi A., Knight D., Amsden B. A biodegradable injectable thermoplastic for localized camptothecin delivery. J. Pharm. Sci. 2004, 93:1195-1204.
20. Landreneau R.J., Sugarbaker D.J., Mack M.J., Hazelrigg S.R., Luketich J.D., Fetterman L., Liptay M.J., Bartley S., Boley T.M., Keenan R.J., Ferson P.F., Weyant R.J., Naunheim K.S. Wedge resection versus lobectomy for stage I (T1 N0 M0) non-small-cell lung cancer. J. Thorac. Cardiovasc. Surg. 1997, 113:691-698. discussion 698-700.
21. Detterbeck F., Rivera M.P., Socinski M.A., Rosenman J. Diagnosis and Treatment of Lung Cancer: An Evidence-Based Guide for the Practicing Physician 2001, W.B. Saunders Company, Philadelphia.
22. Martini N., Bains M.S., Burt M.E., Zakowski M.F., McCormack P., Rusch V.W., Ginsberg R.J. Incidence of local recurrence and second primary tumors in resected stage I lung cancer. J. Thorac. Cardiovasc. Surg. 1995, 109:120-129.
23. Manabe T., Okino H., Maeyama R., Mizumoto K., Tanaka M., Matsuda T. New infusion device for trans-tissue, sustained local delivery of anticancer agent to surgically resected tissue: potential use for suppression of local recurrence of pancreatic cancer. J. Biomed. Mater. Res. B. Appl. Biomater. 2005, 73:203-207.
24. Azab A.K., Kleinstern J., Doviner V., Orkin B., Srebnik M., Nissan A., Rubinstein A. Prevention of tumor recurrence and distant metastasis formation in a breast cancer mouse model by biodegradable implant of 131I-norcholesterol. J. Control. Release 2007, 123:116-122.
25. Zhang L., Hu Y., Jiang X., Yang C., Lu W., Yang Y.H. Camptothecin derivative-loaded poly(caprolactone-co-lactide)-b-PEG-b-poly(caprolactone-co-lactide) nanoparticles and their biodistribution in mice. J. Control. Release 2004, 96:135-148.
26. Zhang L., Yang M., Wang Q., Li Y., Guo R., Jiang X., Yang C., Liu B. 10-Hydroxycamptothecin loaded nanoparticles: preparation and antitumor activity in mice. J. Control. Release 2007, 119:153-162.
27. Wang J., Wang R., Li L.B. Preparation and properties of hydroxycamptothecin-loaded nanoparticles made of amphiphilic copolymer and normal polymer. J. Colloid Interface Sci. 2009, 336:808-813.
28. Shenderova A., Burke T.G., Schwendeman S.P. The acidic microclimate in poly(lactide-co-glycolide) microspheres stabilizes camptothecins. Pharm. Res. 1999, 16:241-248.
29. Zhang C., Ding Y., Yu L.L., Ping Q. Polymeric micelle systems of hydroxycamptothecin based on amphiphilic N-alkyl-N-trimethyl chitosan derivatives. Colloids Surf., B Biointerfaces 2007, 55:192-199.
30. Yang X., Li L., Wang Y., Tan Y. Preparation, pharmacokinetics and tissue distribution of micelles made of reverse thermo-responsive polymers. Int. J. Pharm. 2009, 370:210-215.
31. Hong M., Zhu S., Jiang Y., Tang G., Pei Y. Efficient tumor targeting of hydroxycamptothecin loaded PEGylated niosomes modified with transferrin. J. Control. Release 2009, 133:96-102.
32. Brem H., Mahaley M.S., Vick N.A., Black K.L., Schold S.C., Burger P.C., Friedman A.H., Ciric I.S., Eller T.W., Cozzens J.W., et al. Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas. J. Neurosurg. 1991, 74:441-446.
33. Brem H., Piantadosi S., Burger P.C., Walker M., Selker R., Vick N.A., Black K., Sisti M., Brem S., Mohr G., et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet 1995, 345:1008-1012.
34. Brem H. Polymers to treat brain tumours. Biomaterials 1990, 11:699-701.
35. Shackney S.E., McCormack G.W., Cuchural G.J. Growth rate patterns of solid tumors and their relation to responsiveness to therapy: an analytical review. Ann. Intern. Med. 1978, 89:107-121.
36. DeVita V.T., Lawrence T.S., Rosenberg S.A. DeVita, Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology 2008, Lippincott Williams & Wilkins.
37. Wolberg W.H., Ansfield F.J. The relation of thymidine labeling index in human tumors in vitro to the effectiveness of 5-fluorouracil chemotherapy. Cancer Res. 1971, 31:448-450.
38. Meyer J.S. Cell kinetic measurements of human tumors. Human Pathol. 1982, 13:874-877.